The TRA 2 P-TIMI 50 ( Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50 ) was a randomized , double-blind , placebo-controlled trial of vorapaxar 2.5 mg daily in 26,449 patients with atherosclerosis , stratified by qualifying disease ( MI , PAD , or CVD ) .